Download Programme of the 29th ECNP Congress

Programme of the 29th ECNP Congress - Vienna 2016
1 of 3
http://www.ecnp-congress.eu/programme/AbstractList.aspx#
(/)
Programme of the 29th ECNP Congress Vienna 2016
BACK TO MY SEARCH RESULTS
Session Id: P.3.f
Session title: Psychotic disorders and treatment - Other (clinical)
Session type: Poster session
Evaluation of treatment effects on some antioxidant
markers in schizophrenia
D. Romeo(1), R. Chirita(2), V. Chirita(3)
(1)UMF
Iasi, Iasi, Romania
(2)UMF
Iasi, Medicine, Iasi, Romania
(3)Academia
Oamenilor de Stiinta, Iasi, Romania, Romania
Introduction: Schizophrenia is a common psychiatric disorder, marked by gross distortion
from reality; disturbances in thinking, feeling, and behavior. However, the chemical nature of the
schizophrenic brain is still not completely understood.
Some authors suggested that the damage caused by the occurrence of oxidative stress might
be the biochemical basis of neurodevelopmental abnormalities that are manifested in
schizophrenia. Also, it is believed that oxidative stress may contribute to speci c aspects of
schizophrenic symptomatology and complications of its treatment [1]. However, there are very
few studies that compared the effects of typical vs. atypical antipsychotics on peripheral
oxidative stress markers.
In the present study we wanted to investigate whether there are any differences in the effects
of typical (haloperidol) vs. atypical (quetiapine and olanzapine) antipsychotics on antioxidant
enzymes activities and lipid peroxidation process.
Methods: 30 schizophrenic patients in partial psychotic symptoms remission were selected
8/2/2016 8:00 AM
Programme of the 29th ECNP Congress - Vienna 2016
2 of 3
http://www.ecnp-congress.eu/programme/AbstractList.aspx#
using DSM-IV criteria for schizophrenia. They were of the chronic type, with duration of illness
for at least 5 years and age between 25–60 years.
All patients had been receiving stable doses of oral neuroleptic medications for at least 12
months prior to entry into the study. 15 patients were under haloperidol (approx. 10 mg daily
dose) treatment and 15 patients were under quetiapine (approx. 300 mg daily dose) or
olanzapine (approx. 20 mg daily dose) treatment.
We assessed the levels of some enzymatic antioxidant defences like superoxide dismutase
(SOD) and glutathione peroxidase (GPX), as well as lipid oxidation makers like MDA
(malondialdehyde), from the patients peripheral blood, using chemiluminometric and
spectrophotometric methods.
The results were compared to a normal control group, which was mainly recruited form the
hospital staff, and matched for age and gender.
Results: A signi cant increase of MDA concentration was found in both haloperidol and
atypical antipsychotics treated patients, compared with the control group, suggesting an
increased lipid peroxidation process. Also, the speci c activity of GPX was decreased in both
typical and atypical antipsychotics treated patients, suggesting an increased oxidative status.
However, the activity of SOD was increased in the haloperidol group, compared to the controls.
Additionally, a decrease in the speci c activity of SOD was reported in the atypical (quetiapine
and olanzapine) antipsychotics group.
Conclusions: We found elevated levels of MDA and a decreased activity for the antioxidant
enzymes in the serum of chronically medicated schizophrenic patients regardless of their
treatment type. However, in the case of the atypical antipsychotics the oxidative stress could
be an indicator of illness severity, since quetiapine and olanzapine are formally indicated for a
speci c group of schizophrenic patients, whose symptoms are refractory to other
neuroleptics [2].
Our results could suggest that typical and atypical antipsychotics may not have a direct
regulatory effect on oxidative stress in patients with schizophrenia. Still, it is possible that the
alterations of the antioxidant enzymes and the increased lipid peroxidation products from this
study may re ect the pathological process of the disease.
References
[1] Zhang, X.Y., Tan, Y.L., Cao, L.Y., Wu, G.Y., Xu, Q., Shen, Y., Zhou, D.F., 2006. Antioxidant
enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and
atypical antipsychotics. Schizophr Res. 81, 291–300.
[2] Gama, C.S., Salvador, M., Andreazza, A.C., Kapczinski, F., Silva Belmonte-de-Abreu, P., 2006.
Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in
8/2/2016 8:00 AM
Programme of the 29th ECNP Congress - Vienna 2016
3 of 3
http://www.ecnp-congress.eu/programme/AbstractList.aspx#
schizophrenia: a study of patients treated with haloperidol or clozapine. Prog
Neuropsychopharmacol Biol Psychiatry. 30, 512–515.
Disclosure statement: Currently supported by a PN-II-RU-TE-2014–4–1886 grant called “A
complex study regarding the relevance of oxytocin administration in some animal models of
neuropsychiatric disorders”, number 120 from 01/10/2015.
Keywords:
Schizophrenia: clinical
oxidative stress
Antipsychotic
8/2/2016 8:00 AM